Proprietary Computational Discovery Platform: ProMIS Neurosciences utilizes its unique ProMIS™ computational discovery platform to precisely identify and generate antibodies targeting specific toxic oligomeric forms of misfolded proteins implicated in neurodegenerative diseases.

Highly Specific Therapeutic Candidates: Their therapeutic candidates are designed to selectively bind to and neutralize only the toxic oligomers, aiming to leave beneficial monomeric and fibrillar forms of the protein untouched, potentially leading to improved safety and efficacy profiles.

Potential for Enhanced Safety and Efficacy: By precisely targeting only the pathological forms of proteins, PMN's approach seeks to minimize off-target effects and preserve normal protein function, which could result in better tolerability and more effective disease modification compared to less specific therapies.